SCHEMBL308867

SCHEMBL308867

Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)O)CC1)O2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.71
CACNA1C Q13936 2/20 0.71
CYP2C9 P11712 1/20 0.71
EPHX1 P07099 1/20 0.50
KMT2A Q03164 2/20 0.48
HDAC3 O15379 5/20 0.46
HDAC4 P56524 5/20 0.46
HDAC1 Q13547 5/20 0.46
HDAC7 Q8WUI4 5/20 0.46
HDAC2 Q92769 5/20 0.46
HDAC10 Q969S8 5/20 0.46
HDAC11 Q96DB2 5/20 0.46
HDAC8 Q9BY41 5/20 0.46
HDAC6 Q9UBN7 5/20 0.46
HDAC9 Q9UKV0 5/20 0.46
HDAC5 Q9UQL6 5/20 0.46
ADRA1D P25100 1/20 0.45
KCNH2 Q12809 1/20 0.44
HSD11B1 P28845 1/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741185 0.87 EPHX2 (0.63) EPHX2CACNA1CCYP2C9EPHX1KMT2A
SCHEMBL743411 0.85 EPHX2 (0.59) EPHX2CACNA1CCYP2C9EPHX1HDAC3
Hydrochloric Acid SCHEMBL308726 0.84 EPHX2 (0.58) EPHX2CACNA1CCYP2C9EPHX1HDAC3
SCHEMBL1829504 0.80 EPHX2 (0.55) EPHX2CACNA1CCYP2C9EPHX1KMT2A
SCHEMBL1815677 0.79 EPHX2 (0.56) EPHX2CACNA1CCYP2C9EPHX1KMT2A
SCHEMBL743839 0.79 EPHX2 (0.57) EPHX2CACNA1CCYP2C9EPHX1HDAC3
SCHEMBL731330 0.79 KMT2A (0.53) EPHX2CACNA1CCYP2C9KMT2AHDAC3
SCHEMBL730331 0.78 EPHX2 (0.56) EPHX2CACNA1CCYP2C9EPHX1HDAC3
SCHEMBL741033 0.77 EPHX2 (0.51) EPHX2CACNA1CCYP2C9EPHX1HDAC3
SCHEMBL732918 0.76 EPHX2 (0.51) EPHX2CACNA1CCYP2C9EPHX1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2111406-B1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK SHARP & DOHME (US) 2012-10-24 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 EPHX2 2301/4885CACNA1C 2444/4885CYP2C9 788/4885
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 EPHX2 3190/4885CACNA1C 2083/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.